logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Concert Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 136

% Expired Patents = 28.7



Forward Citations = 1,313

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal Roger D Tung (74 out of 127 patents)

silverMedal Scott L Harbeson (47 out of 60 patents)

bronzeMedal Julie Fields Liu (36 out of 42 patents)

4.  Craig E Masse (17 out of 72 patents)

5.  I Robert Silverman (11 out of 14 patents)

6.  Adam J Morgan (9 out of 19 patents)

7.  Philip B Graham (9 out of 9 patents)

8.  Rose A Persichetti (5 out of 6 patents)

9.  Bhaumik Pandya (4 out of 12 patents)

10.  Emerich Eisenreich (2 out of 5 patents)

11.  Xuejun Karl Liu (2 out of 5 patents)

12.  Robert Silverman (2 out of 2 patents)

13.  Ian Robert Silverman (2 out of 2 patents)

14.  Xuejun Tang (2 out of 3 patents)

15.  Andrew D Jones (2 out of 12 patents)


Core Competencies:
Morphinan Compounds
Deuterated EPI-743
4-Hydroxybutyric Acid Analogs
Deuterated Idebenone
Deuterated Baricitinib
Synthesis of Deuterated Compounds
Inhibitors of UDP-Glucose
Substituted Xanthine Derivatives
Deuterated Rigosertib
Pyrazino[2,1-a]Isoquinoline
Cholesterol Ester Transfer Protein
Derivatives of Gefitinib

136 patents:

1. 12319954 - Morphinan compounds (2025-06-03),
2. 11473123 - Morphinan compounds (2022-10-18),
3. 11267777 - Deuterated EPI-743 (2022-03-08),
4. 11161798 - 4-hydroxybutyric acid analogs (2021-11-02),
5. 10843993 - Deuterated idebenone (2020-11-24),
6. 10842792 - Deuterated baricitinib (2020-11-24),
7. 10813926 - Morphinan compounds (2020-10-27),
8. 10683305 - Deuterated OTX-015 (2020-06-16),
9. 10668036 - Deuterated analogs of D-serine and uses thereof (2020-06-02),
10. 10561659 - Treatment of hair loss disorders with deuterated JAK inhibitors (2020-02-18),
11. 10532971 - 4-hydroxybutyric acid analogs (2020-01-14),
12. 10442761 - Deuterated GFT-505 (2019-10-15),
13. 10406155 - Morphinan compounds (2019-09-10),
14. 10385042 - Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase (2019-08-20),
15. 10357499 - Substituted triazolobenzodiazepines (2019-07-23),
Company Overview
Concert Pharmaceuticals, Inc., based in Lexington, MA, specializes in the development of innovative therapeutics utilizing deuterated compounds. The company focuses on advancing treatments across various therapeutic areas by leveraging its expertise in morphinan compounds and other deuterated analogs. Key research topics include deuterated EPI-743, 4-hydroxybutyric acid analogs, and inhibitors of UDP-glucose, positioning Concert at the forefront of pharmaceutical innovation in the realm of deuterated chemistry.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

136 Patents

#6 in Lexington, MA

#151 in Massachusetts

#2,862 in US

#5,948 in the World

Lexington, MA (US)
Lexington, MA, United States of America

Concert Pharmaceuticals, Inc.

Forward Citations = 1,313

28 inventors:

goldMedal Roger D Tung (74 out of 127 patents)

silverMedal Scott L Harbeson (47 out of 60 patents)

bronzeMedal Julie Fields Liu (36 out of 42 patents)

4.  Craig E Masse (17 out of 72 patents)

5.  I Robert Silverman (11 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Concert Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/concert-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…